Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$793M |
| 2 |
Microsoft
MSFT
|
+$777M |
| 3 |
Coca-Cola
KO
|
+$755M |
| 4 |
Apple
AAPL
|
+$744M |
| 5 |
NVIDIA
NVDA
|
+$718M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Real Estate ETF
VNQ
|
+$251M |
| 2 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$247M |
| 3 |
Oracle
ORCL
|
+$228M |
| 4 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$176M |
| 5 |
MRO
Marathon Oil Corporation
MRO
|
+$140M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.59% |
| 2 | Financials | 12.77% |
| 3 | Consumer Discretionary | 9.88% |
| 4 | Healthcare | 9.85% |
| 5 | Industrials | 8.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3351
Corvus Pharmaceuticals
CRVS
$1.12B
| $160K | ﹤0.01% |
29,968
+14,300
| +91% | +$107K |
|
3352
ClearPoint Neuro
CLPT
$448M
| $159K | ﹤0.01% |
10,369
| – | – |
|
|
HLVX
3353
DELISTED
HilleVax
HLVX
| $156K | ﹤0.01% |
75,596
| – | – |
|
3354
Delcath Systems
DCTH
$422M
| $156K | ﹤0.01% |
+12,977
| New | +$137K |
|
3355
Forafric Global
AFRI
$289M
| $155K | ﹤0.01% |
15,141
+3,204
| +27% | +$33.2K |
|
3356
Ovid Therapeutics
OVID
$414M
| $151K | ﹤0.01% |
161,808
| – | – |
|
|
SERV
3357
Serve Robotics
SERV
$407M
| $151K | ﹤0.01% |
+11,183
| New | +$117K |
|
3358
MediciNova
MNOV
$65.5M
| $150K | ﹤0.01% |
71,506
| – | – |
|
3359
Prelude Therapeutics
PRLD
$366M
| $149K | ﹤0.01% |
117,200
-16,049
| -12% | -$21.3K |
|
3360
Flotek Industries
FTK
$852M
| $148K | ﹤0.01% |
+15,581
| New | +$106K |
|
3361
McEwen Inc
MUX
$1.03B
| $146K | ﹤0.01% |
18,704
| – | – |
|
3362
Atomera
ATOM
$200M
| $145K | ﹤0.01% |
12,488
| – | – |
|
|
CLPR
3363
Clipper Realty
CLPR
$45.2M
| $145K | ﹤0.01% |
31,569
| – | – |
|
3364
Tilly's
TLYS
$116M
| $144K | ﹤0.01% |
33,968
-9,759
| -22% | -$39.8K |
|
|
AKYA
3365
DELISTED
Akoya BioSciences
AKYA
| $144K | ﹤0.01% |
63,002
| – | – |
|
|
ATYR
3366
aTyr Pharma
ATYR
$47.6M
| $144K | ﹤0.01% |
39,689
+13,000
| +49% | +$39.4K |
|
3367
FerroAtlántica
GSM
$594M
| $141K | ﹤0.01% |
37,098
-39,080
| -51% | -$168K |
|
|
GOOS
3368
Canada Goose Holdings
GOOS
$872M
| $141K | ﹤0.01% |
14,003
-14,171
| -50% | -$145K |
|
3369
FibroBiologics
FBLG
$4.26M
| $139K | ﹤0.01% |
3,487
| – | – |
|
3370
Myomo
MYO
$39M
| $138K | ﹤0.01% |
21,495
| – | – |
|
3371
Shattuck Labs
STTK
$675M
| $138K | ﹤0.01% |
114,139
| – | – |
|
3372
Abeona Therapeutics
ABEO
$366M
| $133K | ﹤0.01% |
23,850
| – | – |
|
3373
Personalis
PSNL
$1.35B
| $133K | ﹤0.01% |
22,941
| – | – |
|
|
AGEN
3374
Agenus
AGEN
$312M
| $131K | ﹤0.01% |
47,954
-8,000
| -14% | -$29.6K |
|
3375
Blue Ridge Bankshares
BRBS
$315M
| $131K | ﹤0.01% |
+40,597
| New | +$128K |
|
Similar funds
Charles Schwab's Q4 2024 Portfolio in Review
As of Q4 2024, Charles Schwab held 3,563 positions worth $542B, up 3.5% from $524B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Charles Schwab deployed $17.7B of net new capital in Q4 2024, opening 62 new positions and adding to 2,296 existing holdings. Its largest new stake was Janus Henderson AAA CLO ETF: 3,465,261 shares worth $176M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Vanguard Mortgage-Backed Securities ETF, an estimated $247M trimmed.
- Charles Schwab's largest Q4 2024 buy was Janus Henderson AAA CLO ETF: 3,465,261 shares worth $176M.
- Charles Schwab added most to Amgen in Q4 2024, an estimated $793M increase.
- Charles Schwab's biggest Q4 2024 reduction was Vanguard Mortgage-Backed Securities ETF, cutting an estimated $247M.
- Charles Schwab fully exited Vanguard Real Estate ETF in Q4 2024, selling an estimated $251M.
- Charles Schwab's ten largest holdings make up 23% of its $542B portfolio in Q4 2024.
- Charles Schwab opened 62 new positions and closed 70 in Q4 2024.
- Charles Schwab's portfolio value rose 3.5% quarter-over-quarter to $542B.
Based on Charles Schwab's 13F filing for Q4 2024, filed 6 Feb 2025.